Anti-Fibrinolytic Drugs - Malta | Statista Market Forecast

The Anti-Fibrinolytic Drugs market in Malta is forecasted to achieve a revenue of US$2.58m in 2024.
It is anticipated that the revenue will experience an annual growth rate (CAGR 2024-2029) of 5.51%, leading to a market volume of US$3.38m by 2029.
When compared globally, United States is expected to generate the highest revenue, reaching US$9.86bn in 2024.
Malta is witnessing a growing demand for anti-fibrinolytic drugs, driven by a rising prevalence of bleeding disorders among its population.

Definition:
The Anti-Fibrinolytics market covers drugs which help blood to clot. They are used to treat and prevent bleeding episodes of patients with hemophilia. Moreover, anti-fibrinolytics are used before or during certain surgeries. In doing so, the usage of blood products, such as fresh frozen plasma, as well as the associated risks of infections and/or anaphylactic reactions can be avoided.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Roche, Takeda, Novo Nordisc, Sanofi, Bayer

Inhibitors of fibrinolysis
Drugs to treat hemophilia

Anti-coagulants
Anti-hypertensives
Wound care

Malta, an archipelago in the Mediterranean Sea, has been experiencing a steady growth in its healthcare industry. Among the drugs that have been gaining popularity in the country are Anti-Fibrinolytic Drugs, which are used to treat bleeding disorders.

Customer preferences: The Maltese population has been showing an increasing preference for Anti-Fibrinolytic Drugs due to the rise in the number of patients suffering from bleeding disorders. The country has a high prevalence of hemophilia, a genetic disorder that affects the blood's ability to clot. Patients with hemophilia require regular infusions of Anti-Fibrinolytic Drugs to prevent bleeding episodes.

Trends in the market: The Anti-Fibrinolytic Drugs market in Malta has been growing due to the increase in the number of patients suffering from bleeding disorders. The market has been witnessing a shift towards the use of newer drugs that have fewer side effects and are more effective in preventing bleeding episodes. The trend towards the use of newer drugs has been driven by the increasing awareness among patients and healthcare providers about the benefits of these drugs.

Local special circumstances: Malta has a small population of just over 500,000 people, which means that the market for Anti-Fibrinolytic Drugs is relatively small. However, the country's high prevalence of hemophilia has created a demand for these drugs. The Maltese government provides free healthcare to its citizens, which means that patients with bleeding disorders can receive treatment at no cost. This has helped to increase the demand for Anti-Fibrinolytic Drugs in the country.

Underlying macroeconomic factors: The Maltese economy has been growing steadily in recent years, driven by the country's strong tourism industry and its status as a hub for financial services. The growth of the economy has led to an increase in healthcare spending, which has helped to drive the growth of the Anti-Fibrinolytic Drugs market. The country's membership in the European Union has also helped to boost the healthcare industry by providing access to new drugs and medical technologies.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Bleeding disorders affect the clotting of blood and can result in excessive bleeding inside and outside of the body. Bleeding disorders are almost always inherited and common symptoms include easy bruising, frequent nosebleeds, heavy menstrual bleeding, and excessive bleeding from small cuts. Treatments vary depending on the type of disorder, but may include factor replacement therapy, iron supplementation, topical products or sprays, or blood transfusions. The most common types of bleeding disorders are hemophilia A and B and von Willebrand disease. In 2022, there were around 257,146 people worldwide who had been diagnosed with hemophilia and 100,505 who had been diagnosed with von Willebrand disease.